Risorine

Risorine is a fixed-dose combination (FDC) anti-tuberculosis therapy developed by Cadila Pharmaceuticals in collaboration with the Indian Institute of Integrative Medicine (IIIM), Jammu. It is formulated as a hard gelatin capsule for oral administration and contains rifampicin (200 mg), isoniazid (300 mg), and piperine (10 mg). The inclusion of piperine, a known bioenhancer derived from black pepper, significantly increases the bioavailability of rifampicin. This allows for a reduced rifampicin dose (200 mg) compared to the conventional 450 mg dose used in standard therapy, thereby potentially reducing dose-related side effects such as hepatotoxicity while maintaining clinical efficacy. Rifampicin acts by inhibiting bacterial DNA-directed RNA polymerase, preventing protein synthesis, while isoniazid inhibits the synthesis of mycolic acids required for the mycobacterial cell wall. Risorine is approved and marketed in India for the treatment of drug-susceptible pulmonary tuberculosis.

Brand names

Risorine